A post-hoc analysis of the JADE COMPARE and JADE EXTEND trials reports that abrocitinib maintained early skin clearance and itch relief through 112 weeks in patients with moderate and severe baseline atopic dermatitis. The long follow-up adds weight to durability claims, building on the broader JADE dataset.